Trending
Stocks.org
You are at:»»Celsion Corporation (NASDAQ:CLSN) Analysis Shows Survival Rate Increase For Liver Cancer Patients Treated With ThermoDox; Shares Up
celesion

Celsion Corporation (NASDAQ:CLSN) Analysis Shows Survival Rate Increase For Liver Cancer Patients Treated With ThermoDox; Shares Up

666
By on BioPharma

Celsion Corporation (NASDAQ:CLSN) has announced updated results from its retrospective analysis of the 701-patient HEAT Study of ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary liver cancer.

As of June 30, the latest quarterly Overall Survival (OS) analysis demonstrated that in 41% of the study patients, the combination of ThermoDox and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone. Shares of CLSN are up $0.26, or 7.67%, at $3.65 within a 52-week range of $2.82 – $6.62.

“The post-hoc HEAT Study data is striking in that it has consistently shown a marked OS benefit for ThermoDox plus optimized RFA versus RFA alone in each of the quarterly data sweeps, with this 5th, and final data set demonstrating that this survival benefit is statistically significant,” stated Michael Tardugno, Celsion’s President and Chief Executive Officer. “This impressive clinical data set, together with prospective supportive preclinical study results and multivariate Cox Regression Analyses, reinforces our confidence in the protocol for our Phase III OPTIMA Study in primary liver cancer, which is evaluating ThermoDox in combination with a standardized RFA protocol in primary liver cancer.”

Get Free Updates and Stock Alerts!



*We only send one email per week
Share.

Related Posts

Get Winning Stock Alerts!

Our track record speaks for itself! Our last 7 alerts have delivered combined gains in excess of 300% and there are no signs of slowing down. Join UltimateStockAlerts.com now before you miss out on our next big runner!

We will never sell or share your information.
Close